Kyntra Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kyntra Bio (KYNB).

Price Target Range — 2 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$37Upside to Avg. PT+509.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 17, 2026	Lake Street	Daniel Brims	Initiate	Buy	$41
Sep 1, 2026	HC Wainwright & Co.	Matthew Keller	Maintained	Buy	$43
Jul 7, 2026	Oppenheimer	Jay Olson	Initiate	Outperform	$35
Jun 9, 2026	Rodman & Renshaw	Michael G. King Jr.	Initiate	Buy	$30

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41

Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $41.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.

Benzinga Newsdesk

This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names. See analyst rating changes on top stocks. PFGC, SPCX, KC, WELL, KYNB have coverage initiated.

Avi Kapoor

PRO
Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform rating and announces Price Target of $35.

Benzinga Newsdesk

PRO
Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $30.

Benzinga Newsdesk

What's Going On With Kyntra Bio Stock Tuesday?

Kyntra Bio announces positive data for FG-3246 plus enzalutamide in metastatic castration-resistant prostate cancer.

Vandana Singh

Kyntra Bio Inc

Kyntra Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41

PRO
HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target

This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

PRO
Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30

What's Going On With Kyntra Bio Stock Tuesday?

People Also Watch

People Also Watch

Kyntra Bio Inc

Kyntra Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41

PROHC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target

This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROOppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

PRORodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30

What's Going On With Kyntra Bio Stock Tuesday?

People Also Watch

People Also Watch

PRO
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41

PRO
HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target

PRO
Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

PRO
Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30